Children diagnosed with interstitial lung disease (ILD) are now more likely to survive into adulthood and may thus need care from adult ILD clinics for related impairments and complications. These ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.
Background Patients with interstitial lung disease (ILD) are at risk of developing nocturnal hypoxaemia due to ventilatory restriction and impaired gas exchange that worsen with supine posture and ...
Introduction: There is a growing body of evidence suggesting a causal relationship between interstitial lung disease (ILD) and air pollution, both for the development of the disease, and driving ...
Nerandomilast is under clinical development by Boehringer Ingelheim International and currently in Phase III for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, ...
Los Angeles, CA 90095, USA; dtashkin{at}mednet.ucla.edu Objectives Extent of systemic sclerosis (SSc)-related interstitial lung disease (ILD) assessed from thoracic high-resolution CT (HRCT) predicts ...
Objectives Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, ...
Background Lung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative ...
This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback